MarketPeel
Insider Trading Intelligence
IR

Ilya M. Rachman

IMMX
CEO AND CHAIRMAN · IMMIX BIOPHARMA, INC. · CIK 0001889334
FILING MIX · LIFETIME100%/0%
BUYS
17
SELLS
0
TOTAL VALUE
$53.9K
COMPANIES
1
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
500,000
AVG SELL PX
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 5 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Ilya M. Rachman, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+80.00%+8.40%+0.89%+7.51%+3.65%
14d10+90.00%+18.27%+1.86%+16.41%+5.98%
30d10+80.00%+37.78%+2.20%+35.58%+38.15%
60d10+70.00%+46.87%+1.56%+45.31%+15.88%
90d10+70.00%+60.30%+3.51%+56.79%+31.96%
180d10+80.00%+92.74%+6.34%+86.39%+56.16%
1y10(2 pending)+75.00%+153.17%+12.08%+141.09%+122.40%
2y10(3 pending)+100.00%+191.32%+42.75%+112.23%+48.55%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IMMX · 500,000 shares · as of May 22, 2026
0285,421570,842856,2621,141,68320222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 0 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
500,000500,000May 22, 2026May 29, 2026View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
746$6.67$5.0K1,141,683Dec 10, 2025Dec 10, 2025View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
2,500$2.02$5.0K1,140,937Sep 17, 2025Sep 17, 2025View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
340,000340,000Jun 20, 2025Jun 23, 2025View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
2,178$2.30$5.0K1,138,437Jun 18, 2025Jun 20, 2025View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
340,000340,000Jun 11, 2024Jun 21, 2024View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
2,600$2.13$5.5K1,136,259Jun 7, 2024Jun 10, 2024View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
3,300$1.81$6.0K1,133,659Jun 4, 2024Jun 4, 2024View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
218,3591,130,359May 20, 2024May 20, 2024View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
4,300$2.25$9.7K912,000May 14, 2024May 14, 2024View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
293,000293,000Aug 14, 2023Nov 9, 2023View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
193,000193,000Aug 11, 2023Aug 14, 2023View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
4,050$1.02$4.1K906,550Nov 14, 2022Nov 15, 2022View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
1,000$0.95$950907,550Nov 14, 2022Nov 15, 2022View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
150$0.99$149907,700Nov 14, 2022Nov 15, 2022View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
250,000520,000Jul 14, 2022Jul 18, 2022View →
IMMX
IMMIX BIOPHARMA, INC.
PURCHASE
CEO and Chairman
2,500$5.00$12.5K902,500Dec 20, 2021Dec 20, 2021View →
Other insiders · IMMX
Loading peer insiders…
About this filer
CIK 0001889334
ROLE
CEO and Chairman
PRIMARY
IMMX
COMPANIES
1
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001889334DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback